Weight loss · Indianapolis area, IN
Weight loss and obesity studies in Indianapolis area, IN
14 recruiting studies have a site in the Indianapolis area. This page includes nearby cities such as Carmel, Fishers, Greenwood, Avon.
14 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingPhase 3
A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM
AstraZeneca
- Location
- Indianapolis, IN + 43 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
Eli Lilly and Company
- Location
- Brownsburg, IN + 24 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
Eli Lilly and Company
- Location
- Indianapolis, IN + 59 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event
Eli Lilly and Company
- Location
- Indianapolis, IN + 28 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
Eli Lilly and Company
- Location
- Indianapolis, IN + 36 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingPhase 3
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
Eli Lilly and Company
- Location
- Indianapolis, IN + 34 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingPhase 3
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
Novo Nordisk A/S
- Location
- Indianapolis, IN + 26 other US sites
- Eligibility basics
- Ages 8–18
- RecruitingPhase 3
A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide
Novo Nordisk A/S
- Location
- Indianapolis, IN + 32 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight
Novo Nordisk A/S
- Location
- Indianapolis, IN + 21 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
Amgen
- Location
- Elkhart, IN + 117 other US sites
- Eligibility basics
- Ages 18–99
- RecruitingPhase 4
A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice…
Eli Lilly and Company
- Location
- Indianapolis, IN + 38 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight
Novo Nordisk A/S
- Location
- Indianapolis, IN + 9 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
Novo Nordisk A/S
- Location
- Hammond, IN + 129 other US sites
- Eligibility basics
- Ages 18+
- RecruitingHealthy volunteers
A Sensory Strategy to Cut Sugary Beverages in African/American and Latine Adolescents
Nana Gletsu Miller
- Location
- Indianapolis, IN + 1 other US site
- Eligibility basics
- Ages 12–18
Who these studies look for
Most of these studies set a BMI range and may exclude people taking certain weight-loss medicines or who have had bariatric surgery. Some require a weight-related condition such as type 2 diabetes or high blood pressure.
Matching a page like this one never means you qualify. Each research team decides eligibility at screening.